<DOC>
	<DOCNO>NCT00122538</DOCNO>
	<brief_summary>The purpose study try know antiretroviral combination HIV- infect child one intake day , order simplify prescription improve adherence treatment . This call phase II clinical trial , recruit follow small number child ( 50 ) one year evaluate quantity drug blood take one three hour take . The important objective study tolerance drug mode prescription triple combination .</brief_summary>
	<brief_title>Once-daily Highly Active Antiretroviral Treatment Regimen Administration HIV-1 Infected Children Burkina Faso ( ANRS 12103 BURKINAME )</brief_title>
	<detailed_description>The data relating pharmacology tolerance efficacy once-daily combination 3TC + ddI + EFV never study . This regimen may lead good treatment HIV-1 infect child develop country , well Europe . Because simplicity would facilitate observance one essential parameter efficacy treatment . The main objective phase II clinical trial : - Assess virological immunological efficacy daily HAART regimen comprise lamivudine ( 3TC ) + didanosine ( ddI ) + efavirenz ( EFV ) [ pediatric reference ] ; - Analyse pharmacological characteristic combination child ; - Assess tolerance ; - Study appearance resistance ; - Evaluate observance treatment . 50 HIV-1 infected child age 30 month 15 year whose clinical immunological state ( stage B C ) require antiretroviral treatment , include study . They naive ARV treatment ( except treatment receive framework PMTCT ( Prevention Mother Child Transmission ) . Data Collection Development Study : - Monthly clinical examination ; - RNA HIV-1 CD4 count ; - Pharmacological dosage ; - Haematology biochemistry surveillance ; - Genotypic resistance inclusion ; , case unsuccess failure , - Assessment observance accord alternate method . Laboratory examination carry Centre Muraz except genotyping pharmacological test send Montpellier Teaching Hospital ( France ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 infect child Weight 12 kg Age 30 month Clinical stage require HAART Naive antiretroviral treatment ( except PMTCT prophylaxis ) Mother 's tutor 's informed consent sign HIV2 dual HIV infection Previous antiretroviral therapy Children unable swallow pill Known resistance nonnucleoside reverse transcriptase inhibitor ( NNRTI )</criteria>
	<gender>All</gender>
	<minimum_age>30 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HAART</keyword>
	<keyword>once-daily</keyword>
	<keyword>child</keyword>
	<keyword>africa</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>